|
|
|
Hemcheck's Newsletter - November 2022
|
|
|
In November, we continued pushing our commercial activities and strategic collaboration prospects. We have attended several interesting industry congresses and also received several new orders. We have increasing interest in specifically our diagnostic solution which looks promising and we hope to confirm some additional important orders during the coming weeks.
|
During the month we also signed a new distributor agreement for the Italian market with Levi Biotech. We have already some trials ongoing locally which is very positive. In addition to Italy we are also looking at potential additional distribution agreements for other markets that we do not cover through any partner as of now.
|
|
|
|
Another positive thing was the ISO 13485 certification that we got early in November.
|
In this newsletter you can specifically read a bit more about the ISO certification and our commercial activities during the month.
|
Joen Averstad
|
|
Hemcheck ISO 13485-certified
|
Hemcheck has received the certification according to the quality standard ISO 13485. The certificate has been issued by RISE, Research Institutes of Sweden AB, and is valid for the next three years. The work to specifically prepare the company for the certification began already in the previous year and the certification process has now been fully completed with a successful result. Achieving ISO 13485 certification is important because it shows that the quality management system in the company is on a high level, and can be requested to enable sales, for example when registering products in certain markets.
|
|
|
|
Several follow-up orders in the European market
|
|
UK distributor, Cambridge Life Sciences
|
Hemcheck has received a follow-up order from its British distributor CLS, Cambridge Life Sciences. The order is of smaller size but shows that CLS is active in the market and that British customers are in demand of Hemcheck’s products.
|
|
|
Tartu University Hospital, Estonia
|
Hemcheck has received a follow-up order from Tartu University Hospital in Estonia. The hospital already uses Hemcheck’s products on an ongoing basis and this order means an increase in the number of instruments, which provides a one-time income, while it may mean increased ongoing income for Hemcheck depending on the use. The instruments are intended to be used in the laboratory and in the hematology/oncology department, and both for quality control and diagnostics.
|
|
|
Czech distributor, Promedicia
|
Hemcheck has received a small follow-up order from Promedica, a Czech distributor. The order concerns bgs-Test and v-Test.
|
|
|
Distribution agreement & follow-up order from its Italian distributor, Levi Biotech
|
Hemcheck has signed a distributor agreement with Levi Biotech regarding the Italian market. The agreement is for three years and entails a first order during the fourth quarter, like previous similar agreements. In addition Levi Tech has placed a small follow-up order in connection with the signing of the agreement.
|
|
|
Greek distributor, Anticel
|
Hemcheck´s Greek distributor Antisel places an additional follow-up order. The order is of lower economic value, but shows again that Antisel is active in the market and that Greek customers demand Hemcheck’s products.
|
|
|
|
Update on our commercial activities
|
We have continued our sales efforts including attending industry meetings and congresses during the month. These are very important in order to meet potential customers, key opinion leaders and potential partners. Below you can find some examples of events we have attended recently.
|
|
|
|
ACBI 2022 is an annual conference for Clinical Biochemists in Ireland. Hemcheck attended as support to our Irish distributor Cruinn Diagnostics. During the conference the Hemcheck concept was showcased exclusively via a test study performed at Cork University Hospital. Follow up activities are planned with several hospitals in Ireland.
|
The congress is the main event for laboratory diagnosticians in Poland. Hemcheck attended the congress as support to their Polish partner, Eclipse. They participated as exhibitors, showcasing the Hemcheck concept. Contacts with several interested delegates are being followed up.
|
|
|
|
ESAIC is the largest professional community of anaesthesiologists and intensivists in Europe. Hemcheck attended the community as an exclusive exhibitor, supported by their distributor in Spain, SDO Medical. Contacts with several interested delegates from different countries will be followed up by Hemcheck and their distributors/partners in concerned countries.
|
EACTS is the European association of cardio-thoracic surgery and Hemcheck exhibited with our own booth at the meeting, with the focus of showcasing our solution for diagnostic purposes.. Several contacts were made with potential new and current customers as well as potential partners for the German market.
|
Peter Andersson
Sales & Marketing Manager
|
|
|
|
|
|
|
|
|
|
|